BioSpace News Archive

DeBogy Molecular, Inc, a biotech startup that specializes in antimicrobial surface modification, today announced the findings of a landmark in vivo research study that affirms the effectiveness and safety of their new technology to kill the dangerous bacteria that proliferates on the surface of a medical implant following surgery.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it will pursue a direct to OTC regulatory pathway for Epoladerm™.

Having recently accepted the positions of CEO and Director of Cell MedX, I wanted to introduce myself to you, highlight the Company’s most recent accomplishments and our vision for the future.

Cervical cancer is a type of cancer affecting the cervix. Various strains of the human papillomavirus (HPV), a sexually transmitted infection, play a major role in causing cervical cancer.

KIO-301 is a visible light-sensitive small molecule that acts as a reversible ‘photoswitch’, specifically designed to restore the eyes’ ability to perceive and interpret light in visually impaired patients.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced database lock for the Company’s ONWARD Phase 3 clinical trial.

The U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.

According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Moreover, as per the same source, about 70% of all cancer deaths occur in low- and middle-income countries.

The global CAR T-cells therapy market size reached USD 1.29 Billion in 2021 and is expected to register a revenue CAGR of 24.9% during the forecast period, according to latest analysis by Emergen Research.

The global home healthcare market size was USD 179.56 Billion in 2020 and is expected to register a revenue CAGR of 8.4%, during the forecast period, according to latest analysis by Emergen Research.